AMWatch

Milliardærfamilie vender blikket mod biotek: Investerer millioner i kræftfirma fra Lyngby

Kunøe-familien, som har tjent milliarder på succesfulde investeringer, dypper for første gang tæerne i life science-branchen og har foretaget en millioninvestering i et dansk biotekselskab, der er spundet ud fra DTU Nanotech. Flere investeringer på vej.

Lone Kunøe er adm. direktør i Consolidated Biosciences, der er Kunøe-familiens investeringsselskab med fokus på life science. | Photo: Fotograf Søren Brissing

It-branchen har været god ved Kunøe-familien.

Gennem store aktieposter i blandt andre de børsnoterede selskaber Atea og Columbus har familien skabt sig en stor milliardformue, som er investeret i mange dele af dansk erhvervsliv, og nu rykker familien ind som investor i et nyt område. Life science.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

The ESG market is controlled by a few big investors

Finland's largest investor holds 62 percent of shares of multi-trillion ETFs offered by iShares and 64 percent of Xtrackers' equivalent offering. Having a few investors dominating ownership in this way is not good for the vehicles' liquidity and could be a big challenge facing the sector.

"We continue to see further growth in our Nordic book of business"

DECEMBER SERIES: What were the most important developments at some of the global asset managers present on the Nordic market in 2021, and what are their expectations for the coming year? AMWatch's December series is kicked off by Head of Nordics at State Street Global Advisors, Arnaud Bruyneel. 

Related articles

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch